Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60612


Purpose:

The aim of the study is to compare the safety & efficacy of sertraline (up to a dose of 200mg/day) & pregabalin (up to a dose of 300mg/day)for the treatment of symptoms of anxiety in patients with epilepsy.


Criteria:

Inclusion Criteria: - GAD-7 total score above 10. - Have a diagnosis of a Partial Seizure Disorder. - Have a Hamilton-A total score 20 and above. - 18-80 years of age. - Able to read at a fourth grade level. - If a woman of childbearing age, agrees to use an acceptable means of birth control. Exclusion Criteria: - Unable to understand and sign a consent. - Unable to follow instructions for the study. - Displaying current suicidal ideation - Having psychogenic non-epileptic seizures - Have a history of drug or alcohol abuse. - Use of any investigational drug within the last 30 days. - Hypersensitivity reaction or other serious adverse event to PGB in prior trials.


NCT ID:

NCT01309074


Primary Contact:

Principal Investigator
Andre M. Kanner, MD
Director Laboratory Encephalography, Associate Director Section of Epilepsy and Rush Epilepsy Center


Backup Contact:

N/A


Location Contact:

Chicago, Illinois 60612
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.